SUPN241220P38000
- 3.00
- 0.000.00%
Supernus Pharmaceuticals Newsroom
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Numerous Supernus Pharmaceuticals Insiders Sold Stock: Not A Positive Omen
US Manufacturing Index Rises To 43, Highest Since 2020
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$4.54 Million in Common Stock
Form 144 | Supernus Pharmaceuticals(SUPN.US) Officer Proposes to Sell 4.54 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 8, $Supernus Pharmaceuticals(SUPN.US)$ Officer JACK A KHATTAR intends to sell 125K shares of its common stock on Nov 8, with a total market value of approximately $4.54
Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$4.59 Million in Common Stock
Form 144 | Supernus Pharmaceuticals(SUPN.US) Officer Proposes to Sell 4.58 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 7, $Supernus Pharmaceuticals(SUPN.US)$ Officer JACK A KHATTAR intends to sell 125K shares of its common stock on Nov 7, with a total market value of approximately $4.58
Earnings Call: Supernus Pharmaceuticals Reported a Significant Increase in Total Revenue
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Strong Q3 Performance and Promising Future for Supernus Pharmaceuticals Backed by Qelbree's Success
Supernus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Supernus Pharmaceuticals | 8-K: Supernus Announces Third Quarter 2024 Financial Results
Express News | Supernus Pharmaceuticals Sees FY24 Total Revenue $630M-$650M Vs $619.505M Est
Supernus Pharmaceuticals Q3 2024 GAAP EPS $0.69 Beats $0.02 Estimate, Sales $175.689M Beat $157.298M Estimate